Back HIV/AIDS HIV/AIDS Topics HIV Treatment

HIV Drug Therapy: Doravirine Works as Well as Efavirenz with Fewer CNS Side Effects

Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side effects, researchers reported this week at the International Congress on Drug Therapy in HIV Infection in Glasgow.

alt

Read more:

Gilead Submits Request for FDA Approval of Tenofovir Alafenamide Coformulation

Gilead Sciences this week announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-tablet regimen containing tenofovir alafenamide (TAF) -- a new version of the widely used antiretroviral that causes less kidney and bone toxicity -- coformulated with its new integrase inhibitor elvitegravir, cobicistat, and emtricitabine.

alt

Read more:

HIV Drug Therapy: Efavirenz Compromises Hormonal Contraceptive Implant

The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in developing countries, according to findings from a study conducted in Uganda presented this week at the HIV Drug Therapy Glasgow conference.

alt

Read more:

HIV Drug Therapy: Australia Performs Best in HIV Treatment Cascade -- 62% Undetectable Viral Load

Australia and northern European countries are doing far better than North America at retaining people living with HIV in care and achieving viral suppression, according to a comprehensive survey of treatment cascades in high-income countries presented this week at the International Congress on Drug Therapy in HIV Infection in Glasgow.

alt

Read more:

HIV R4P: Injectable Rilpivirine Shows Promise, May Work Better for Anal than Vaginal Sex

A Phase 1 dose-finding and safety study in humans of TMC278-LA, a long-acting, injectable formation of the antiretroviral drug rilpivirine, found that a single 1200 mg dose could produce sustained drug levels in rectal tissues that could offer protection against HIV for 3 months, and did in fact suppress viral replication in so-called explants (biopsies of rectal mucosal cells) for that length of time. However -- and to the surprise of researchers presenting this study at the HIV Research for Prevention conference last week in Cape Town -- drug levels in vaginal and cervical cells were only about half of those seen in rectal cells, and viral replication was not suppressed in vaginal and cervical biopsies taken from women given TMC278-LA.

alt

Read more:

HIV Drug Therapy: Do Emtricitabine and Lamivudine Have Similar Efficacy for First-line ART?

First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the October 1 online edition of Clinical Infectious Diseases and at the HIV Drug Therapy Glasgow conference taking place this week. Lamivudine was associated a significantly increased risk of virological failure when used in these regimens.

alt

Read more:

HIV and Hepatitis C Highlights from AIDS 2014

Latest Positive Pulse Newsletter

Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss highlights from this summer's International AIDS Conference, the largest and most comprehensive global meeting on the medical, public health, and social aspects of HIV and AIDS.

Highlights of this overview include the HIV cascade of care, developments in antiretroviral therapy, pre-exposure prophylaxis (PrEP) and other HIV prevention news, and new hepatitis C treatment for people with HIV/HCV coinfection.

10/22/14

alt